El interés en corto de Italgas da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Italgas. Los datos de interés en corto se actualizan cada dos semanas.

Italgas (OTC:ITGGF) Bolsa, Informe de interés en corto

Italgas SpA is an Italy-based company engaged in the business of natural gas distribution. The distribution service consists of transporting gas through local pipeline networks, from points of delivery at the reduction and measurement stations interconnected with the transport networks up to the final delivery points to customers. In addition, the company is also engaged in metering activities, which consist of determining, gathering, making available, and archiving metering data on natural gas withdrawn over the distribution networks. It derives a majority of its revenue from natural gas distribution activity. The other activities of the company are the distribution and sale of water and providing technical, engineering, IT assistance, and other services.

Italgas SpA

Barclays analyst Betty Jiang maintains EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) with a Equal-Weight and lowers the price target from $144 to $137.

News

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on EOG Resources, Lowers Price Target to $137

<a href="https://x.com/MartinShkreli/status/1841862853646512292" title="https://x.com/MartinShkreli/status/1841862853646512292">https://x.com/MartinShkreli/status/1841862853646512292</a>

Trading Ideas

SAVA

Watching Cassava Sciences; Shares See Volume As Traders Circulate Martin Shkreli X Post Mentioning The Stock

Barclays analyst Theresa Chen maintains Enbridge (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ENB#TSX">ENB</a>) with a Equal-Weight and raises the price target from C$53 to C$54.

TSX:ENB

Barclays Maintains Equal-Weight on Enbridge, Raises Price Target to C$54

WIIM

MKTX

MarketAxess shares are trading higher after the company reported a year-over-year increase in Q3 and September trading volume and transaction fees.

Barclays analyst Christine Cho maintains DT Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTM#NYSE">DTM</a>) with a Overweight and raises the price target from $76 to $85.

Barclays Maintains Overweight on DT Midstream, Raises Price Target to $85

Looking into the current session, Rocket Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) shares are trading at $18.70, after a 0.80% decrease. Over the past month, the stock decreased by 8.06%, but over the past year, it actually increased by 129.03%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1727969484_0.png" alt="Past Year Chart" />

<h3>Rocket Companies P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Rocket Companies has a better P/E ratio of 209.44 than the aggregate P/E ratio of 29.33 of the Financial Services industry. Ideally, one might believe that Rocket Companies Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1727969484_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

Price Over Earnings Overview: Rocket Companies

Barclays analyst Betty Jiang maintains Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) with a Equal-Weight and lowers the price target from $55 to $46.

Barclays Maintains Equal-Weight on Devon Energy, Lowers Price Target to $46

Barclays analyst Betty Jiang maintains Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) with a Overweight and lowers the price target from $33 to $31.

CTRA

Barclays Maintains Overweight on Coterra Energy, Lowers Price Target to $31

The cannabis sector has captivated investors, promising a green rush of potential profits. However, the path to profitability has been rocky, marked by regulatory hurdles, intense competition, and, at times, a volatile market. Many investors are left wondering: Is the cannabis sector still a viable long-term investment, or is the green rush fading? While not simple, the answer increasingly indicates a positive outlook driven by evolving regulations and strong market fundamentals.
<h2>A Budding Legal Landscape</h2>
The cannabis industry is undergoing a significant transformation that is being driven by a changing regulatory environment. The acceptance of medical and recreational cannabis is increasing across many jurisdictions. This trend is particularly evident in the United States, where a growing number of states have legalized recreational cannabis, creating an expanding market.
While federal legalization in the U.S. remains a hurdle, the potential for it is undeniable. Should it occur, federal legalization would likely trigger a significant surge in industry growth and investment, leading to market stability and a more favorable business environment. This evolving regulatory landscape represents a key driver for the cannabis sector, making it an increasingly attractive investment opportunity for those with a long-term perspective.
<h2>Fueling the Green Rush: Market Drivers</h2>
The cannabis sector&#39;s growth is driven by multiple factors that make it increasingly attractive for investors. Consumer demand is surging, fueled by shifting perceptions of cannabis and the increasing availability of diverse products catering to a wide range of consumer preferences.
Moreover, the medical cannabis segment is experiencing rapid growth, driven by advancements in research and the development of new cannabis-based therapies. Medical cannabis is being explored for its potential to treat a wide range of conditions, creating new opportunities for companies focused on this sector.
Finally, the cannabis market is expanding beyond established jurisdictions like Canada and the United States. As more countries legalize cannabis, the global market is poised to reach new heights, offering significant growth opportunities for cannabis companies with international reach.
<h2>Leading Cannabis Companies Show Signs of Progress&nbsp;</h2>
The surge in consumer demand, fueled by changing perceptions and diverse product offerings, attracts significant investment in the cannabis sector. This is evident in the performance of leading companies, many demonstrating a shift towards profitability and a more focused approach to growth.
For example, Aurora Cannabis (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acb#NASDAQ">ACB</a>) recently achieved a significant milestone by reporting positive free cash flow for the first time. Aurora&#39;s earnings report for the first quarter of fiscal 2025 revealed a positive free cash flow of $6.5 million, reflecting a strategic focus on cost management and operational efficiency.
This shift is further exemplified by Aurora&#39;s strategic move towards the higher-margin medical cannabis segment, leveraging its expertise and resources to capitalize on the growing demand for medical cannabis products. In Q1 2025, Aurora reported record revenue in its global medical cannabis segment, indicating a successful shift towards this lucrative niche.
While Aurora has made significant progress, it still faces challenges, such as ongoing competition and the need for continued fiscal discipline. However, the company&#39;s recent achievements signal a positive trajectory for its future, especially considering its debt-free status, which allows for more financial flexibility.
Canopy Growth (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NASDAQ">CGC</a>) has taken a different path, prioritizing profitability and cost control over rapid growth. This strategic shift has significantly improved the company&#39;s Adjusted EBITDA, demonstrating its commitment to generating sustainable profits. In Q1 2025, Canopy&#39;s Adjusted EBITDA loss narrowed by over 75% compared to the previous year, highlighting the company&#39;s success in cost control and operational efficiency.&nbsp;
This success is also reflected in the company&#39;s recent debt reduction efforts, securing a favorable amendment to its term loan agreement, further enhancing its financial flexibility. The company&#39;s focus on expanding into key markets like Germany, where it is augmenting its Canadian-sourced flower with EU-based supply to meet growing demand, showcases its ambition to capture a larger share of the global medical cannabis market.
Canopy Growth, like Aurora, still needs to address its ongoing losses. Despite recent improvements, the company remains unprofitable, which is a concern for investors seeking a consistent return on their investment. Additionally, the cannabis industry is prone to volatility, and Canopy&#39;s stock price has been highly volatile in recent years, requiring investors to have a strong risk tolerance.
<h2>Beyond the Individual Stock: The Power of Cannabis ETFs</h2>
For investors seeking diversified exposure to the cannabis sector without choosing individual stocks, Cannabis ETFs offer a convenient option. The AdvisorShares Pure U.S. Cannabis ETF (ARCA:MSOS) is a good starting point, offering investors a basket of publicly traded U.S. cannabis companies.
While ETFs can provide diversification and access to a broader market, it&#39;s important to remember that they are not without risks. ETFs are subject to market volatility, and the performance of the underlying companies within the ETF can impact their performance.
<h2>The Green Rush Continues</h2>
While the path has not been easy, the cannabis sector continues to demonstrate significant potential for long-term growth. The changing regulatory environment is creating a more favorable landscape for cannabis companies, while solid market fundamentals are driving consumer demand and fueling industry expansion.&nbsp;
The ongoing developments in medical cannabis research are further bolstering the sector&#39;s potential, while the emergence of new markets and the growing popularity of diverse cannabis products are contributing to the industry&#39;s growth trajectory.
Investors who conduct thorough research, manage risk effectively, and maintain a long-term perspective can position themselves to capitalize on the potential rewards of this evolving and dynamic sector. The green rush may be ongoing, but navigating its complexities requires careful planning and a thoughtful investment strategy.
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/profit-from-the-green-wave-top-cannabis-stocks-to-watch/">Profit from the Green Wave: Top Cannabis Stocks to Watch</a>&quot; first appeared on MarketBeat.

Cannabis

Earnings

Government

Penny Stocks

Regulations

Sector ETFs

Offerings

Small Cap

ETFs

MSOS

Profit from the Green Wave: Top Cannabis Stocks to Watch

The cloud battle between Oracle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) and Salesforce Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) is hitting new highs, and both stocks are riding the AI wave <a href="https://www.benzinga.com/topic/artificial-intelligence">to impressive gains</a>.
But which one is winning? Let's dive into the numbers, recent moves, and what investors need to know.
<h2 class="wp-block-heading">Oracle's Big Play: Malaysia's Mega Cloud</h2>
Oracle has been flexing its cloud muscles, with a 20% stock jump over the past month, +61% YTD, thanks to impressive growth in its cloud infrastructure services. The latest boost? 
A $6.5 billion investment to establish a public cloud region in Malaysia—outpacing Amazon.com Inc's $6.2 billion AWS plan. Oracle's aggressive push aims to tap into Malaysia's growing demand for AI, data, and analytics, potentially becoming one of the largest tech investments in Southeast Asia.
Read Also: <a href="https://www.benzinga.com//node/41139192">Oracle Bets Big: Plans Over $6.5B Cloud Expansion In Malaysia To Fuel AI Innovation</a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="459" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03094546/Screenshot-2024-10-03-at-5.36.35-PM.png" alt="" class="wp-image-578711" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03094546/Screenshot-2024-10-03-at-5.36.35-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03094546/Screenshot-2024-10-03-at-5.36.35-PM-300x219.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100324&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
On the charts, Oracle stock is showing solid bullish signals across the board, trading at $167.71, above its eight-day, 20-day and 50-day moving averages. However, some selling pressure indicates caution for those diving in for short-term gains. 
Still, with ambitious revenue targets of $104 billion by FY2029, Oracle is playing the long game.
<h2 class="wp-block-heading">Salesforce: GenAI Power Move</h2>
Meanwhile, Salesforce isn't standing still. The stock is up 12.67% in the last month, powered by its new AgentForce platform, <a href="https://www.benzinga.com//node/41145130" target="_blank" rel="noopener">which analysts have hailed as "on par"</a> with Microsoft Corp's GenAI.
Piper Sandler even upgraded Salesforce to Outperform with a price target of $400. AgentForce, designed for sales, marketing, and service workflows, could boost Salesforce's TAM by a whopping $3.2 trillion. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100324&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="459" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03094733/Screenshot-2024-10-03-at-5.36.23-PM.png" alt="" class="wp-image-578714" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03094733/Screenshot-2024-10-03-at-5.36.23-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/03094733/Screenshot-2024-10-03-at-5.36.23-PM-300x219.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100324&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Salesforce stock&#8217;s bullish technical signals, trading at $279.48, above its eight-day, 20-day and 50-day moving averages, confirm strong buying pressure.
<h2 class="wp-block-heading">The Verdict?</h2>
Both Oracle and Salesforce are AI-driven, cloud-hungry giants with plenty of growth potential. Oracle's bold infrastructure moves in Asia give it global reach, while Salesforce's GenAI ambitions position it to dominate in enterprise software. 
Investors eyeing cloud and AI should consider both—but Oracle's international ventures and bullish long-term outlook might edge out Salesforce's innovative short-term wins.
The real question: Who will be the ultimate king of the cloud? Let's see how the AI boom unfolds.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/technicals/24/09/41002243/oracle-surges-20-in-september-as-ai-cloud-strategy-flashes-bullish-signals">Oracle Surges 20% In September As AI, Cloud Strategy Flashes Bullish Signals</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Technicals

Tech

ORCL

Oracle Vs. Salesforce: Cloud Wars Heat Up, Stocks Take Off

Barclays analyst Betty Jiang maintains ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) with a Overweight and lowers the price target from $156 to $135.

Barclays Maintains Overweight on ConocoPhillips, Lowers Price Target to $135

Zomedica Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZOM#NYSE">ZOM</a>) shares are trading higher on Thursday. The company disclosed the expansion of its <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/ac41160353/zomedica-announces-expansion-of-exclusive-equine-distribution-agreement-with-grovet-in-europe" rel="noreferrer noopener">distribution partnership with </a><a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/ac41160353/zomedica-announces-expansion-of-exclusive-equine-distribution-agreement-with-grovet-in-europe" rel="noreferrer noopener">Grovet</a>.
The updated agreement grants Grovet exclusive equine distribution rights for Zomedica&#8217;s PulseVet and TRUFORMA product platforms across 27 countries in Europe.
The updated agreement gives Grovet exclusive rights to distribute Zomedica&#8217;s PulseVet and TRUFORMA equine products in 27 European countries, including Germany, France, and Spain. Distribution in Italy and the U.K. will be non-exclusive.
Related: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/08/40366111/zomedica-taps-into-costa-rica-with-strategic-partnership-with-sire-veterinario" rel="noreferrer noopener">Zomedica Taps Into Costa Rica With Strategic Partnership With SIRE Veterinario</a>
The agreement not only expands PulseVet distribution to more European countries but also adds the TRUFORMA platform, equine eACTH and Cortisol assays, and the upcoming equine Insulin assay to Grovet&#8217;s product offerings.
Koen Schmitz-Managing Director of Grovet said, &#8220;We only partner with companies whose products are rooted in scientific studies, and all of Zomedica&#8217;s products we are carrying are exactly just that, rooted in science and steeped in research.&#8221;
Brandon Marino, Senior Director of Global Channels for Zomedica, said, &#8220;Grovet has been a great partner to Zomedica for the equine PulseVet product line over the last several years, and they were the perfect partner to help expand the reach of our TRUFORMA equine platform within Europe.&#8221;&nbsp;
Price Action: ZOM shares are up 2.53% at $0.1337 at the last check Thursday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41163538" target="_blank" rel="noreferrer noopener">Starbucks Invests In Future-Proof Coffee: New Farms In Latin America And Beyond To Tackle Climate Challenges</a></li>
</ul>

Equities

Zomedica Strengthens European Foothold With Grovet Partnership, Expanding PulseVet And TRUFORMA Reach

TD Cowen analyst Oliver Chen maintains Levi Strauss (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) with a Buy and lowers the price target from $25 to $23.

LEVI

TD Cowen Maintains Buy on Levi Strauss, Lowers Price Target to $23

The demand for GLP-1 agonists, including Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic and Wegovy (semaglutide), a class of drugs used to manage diabetes and obesity, continues to grow.
Though initially developed for type 2 diabetes, GLP-1s have gained attention for their effectiveness in weight management. The FDA approval expanded use for <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37567088/novo-nordisks-game-changer-fda-approves-weight-loss-sensation-wegovy-for-heart-health-potential-i" rel="noreferrer noopener">cardiovascular indication for Wegovy</a> and potential future applications for chronic kidney disease and non-alcoholic steatohepatitis (NASH) further underscores the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41034046/popular-ozempic-may-have-new-use-as-semaglutide-drugs-linked-to-reduced-overdose-risk-in-diabetic" rel="noreferrer noopener">promise of these treatments</a>.
The Forbes report <a target="_blank" href="https://www.forbes.com/sites/joshuacohen/2024/10/02/weight-loss-from-glp-1-drugs-not-as-robust-in-real-world-settings/" rel="noreferrer noopener">adds</a> that real-world evidence shows that weight loss from GLP-1 usage may not align with the outcomes seen in clinical trials.
A study published in the Journal of the American Medical Association (JAMA) revealed that patients, on average, achieved only a 3.7% weight reduction after one year on the drugs—lower than the results reported in controlled trials.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40986953/novo-nordisk-ceo-to-face-senate-scrutiny-over-high-ozempic-and-wegovy-prices-hearing-scheduled-on" rel="noreferrer noopener">Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday</a>.
While patients have high expectations for substantial weight loss, the findings suggest that most individuals did not experience the same degree of benefit as seen in clinical settings.
However, those who persisted with GLP-1 therapy saw results comparable to those in clinical trials.
In another study published in 2023, researchers observed a modest average weight loss of 2.2% over 72 weeks among type 2 diabetes patients on GLP-1s.
Additionally, a pre-print analysis this year found that the real-world effectiveness of GLP-1s was less pronounced than in randomized controlled trials.
This difference underscores the challenge of replicating clinical trial success in everyday medical settings, where factors like medication adherence and real-life conditions are involved.
Persistence with GLP-1 medications is a significant issue. Forbes reported that only 15% of patients who started GLP-1 drugs for weight loss remained on them after two years, citing Prime Therapeutics, a pharmacy benefit manager.
Discontinuation rates were high, with just 29% continuing treatment after one year and a mere 15% after two years.
Other studies, including findings from Blue Cross Blue Shield, show that many patients stop GLP-1 therapy early, often within the first month, before achieving meaningful weight loss.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41166018/medicare-drug-price-negotiation-program-gets-final-guidance-for-second-cycle-1-5b-savings-expecte" target="_blank" rel="noreferrer noopener">Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected</a>.</li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

Media

General

Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals

Barclays analyst Betty Jiang maintains Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) with a Overweight and lowers the price target from $185 to $168.

Barclays Maintains Overweight on Chevron, Lowers Price Target to $168

Barclays analyst Betty Jiang maintains California Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRC#NYSE">CRC</a>) with a Equal-Weight and raises the price target from $55 to $57.

Barclays Maintains Equal-Weight on California Resources, Raises Price Target to $57

BWXT

BWX Technologies shares are trading higher after Deutsche Bank maintained a Buy rating on the stock and raised its price target from $113 to $129.

Levi Strauss &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEVI#NYSE">LEVI</a>) shares are trading lower Thursday after the company posted worse-than-expected third-quarter <a href="https://www.benzinga.com/news/earnings/24/10/41151280/levi-strauss-co-stock-falls-after-mixed-q3-results-eps-beat-revenues-miss">revenue on Wednesday</a>.
The Details:
Levi Strauss reported quarterly revenue of $1.516 billion, below consensus estimate of $1.55 billion, due in part to the exit of its Denizen business. The company also revealed it&#8217;s <a href="https://www.benzinga.com/markets/equities/24/10/41156870/levi-strauss-considers-dockers-sale-what-this-means-for-the-iconic-denim-brand">considering a sale</a> of its Dockers brand. 
"We are narrowing our focus to realize the full potential of the Levi's brand as well as accelerate Beyond Yoga. Accordingly, we are undertaking an evaluation of strategic alternatives for the global Dockers business," CEO Michelle Gass said during a post-earnings call.
Read Next: <a href="https://www.benzinga.com/news/24/10/41152629/what-happened-with-accenture-stock-today">What Happened With Accenture Stock Today?</a>
Levi Strauss issued fiscal 2024 earnings guidance with its midpoint below estimates. The company expects earnings of between $1.17 and $1.27 per share for the year, versus the $1.25 estimate.&nbsp;
Stifel analyst Drew Crum maintained a Buy rating and lowered the price target from $28 to $25 following the print. Telsey Advisory Group maintained its Outperform rating and $26 price target.
<h3 class="wp-block-heading">Should I Sell My LEVI Stock?</h3>
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
Shares of Levi Strauss have gained 48.15% year to date. This compares to the average annual return of -3.24%, meaning the stock has outperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity. 
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Levi Strauss stock currently has an RSI of 56.58, indicating neutral conditions.
For analysis tools, charting data and access to exclusive stock news, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a> 
LEVI Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Levi Strauss &amp; Co shares are down 7.22% at $19.54 at the time of publication Thursday.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41122476/whats-going-on-with-microstrategy-stock">What&#8217;s Going On With MicroStrategy Stock?</a></li>
</ul>
Image: Shutterstock&nbsp;

Movers

What's Going On With Levi Strauss Stock After Earnings?

Barclays analyst Christine Cho maintains Array Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) with a Overweight and lowers the price target from $11 to $10.

ARRY

Barclays Maintains Overweight on Array Technologies, Lowers Price Target to $10

TD Cowen analyst Helane Becker maintains Allegiant Travel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGT#NASDAQ">ALGT</a>) with a Hold and raises the price target from $33 to $42.

Comments

Italgas

Interés en corto

Italgas (OTC:ITGGF) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL